Damora Therapeutics
DMRA
Damora Therapeutics (DMRA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$2.60
- EPS estimate
- $0.00
- EPS surprise
- +0.00%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 5, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | $0.00 | −$2.60 | +0.00% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | $0.00 | −$1.92 | +0.00% | $0.00 | SEC |
| Q3 2024 | Nov 1, 2024 | −$3.70 | −$3.39 | +8.38% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$6.04 | −$4.92 | +18.48% | $0.00 | SEC |
| Q1 2024 | Apr 29, 2024 | −$10.25 | −$5.05 | +50.73% | $0.00 | SEC |
| Q4 2023 | Mar 8, 2024 | −$8.75 | −$5.97 | +31.83% | $0.00 | SEC |
| Q3 2023 | Nov 6, 2023 | −$8.50 | −$7.50 | +11.76% | $0.00 | SEC |
| Q2 2023 | Jul 31, 2023 | −$14.67 | −$10.25 | +30.11% | $0.00 | SEC |
| Q1 2023 | Apr 28, 2023 | −$15.63 | −$12.75 | +18.40% | $0.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$14.25 | −$13.75 | +3.51% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$17.00 | −$13.50 | +20.59% | $0.00 | — |
| Q2 2022 | Jul 29, 2022 | −$17.25 | −$16.75 | +2.90% | $0.00 | — |
| Q1 2022 | Apr 29, 2022 | −$15.25 | −$16.75 | −9.84% | $0.00 | — |
| Q4 2021 | Feb 17, 2022 | −$14.00 | −$13.25 | +5.36% | $0.00 | — |
| Q3 2021 | Nov 4, 2021 | −$14.00 | −$12.50 | +10.71% | $0.00 | — |
| Q2 2021 | Aug 5, 2021 | −$13.50 | −$12.25 | +9.26% | $0.00 | — |
| Q1 2021 | May 4, 2021 | −$11.50 | −$13.25 | −15.22% | $0.00 | — |
| Q4 2020 | Mar 29, 2021 | −$22.95 | −$11.75 | +48.79% | $0.00 | — |
| Q3 2020 | Dec 11, 2020 | −$340.06 | −$19.00 | +94.41% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Damora Therapeutics (DMRA) last report earnings?
Damora Therapeutics last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did DMRA beat earnings estimates?
Damora Therapeutics reported EPS of −$2.60 for Q2 2025, in line with the $0.00 consensus estimate.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.